Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
A&O Shearman has advised global biopharma GSK on its licensing agreement with Suzhou Siran Biotechnology Co., Ltd., a biotech company specializing in siRNA drug development, under which SiranBio will exclusively license to GSK on a worldwide basis (excluding mainland China, Hong Kong, Macau, and Taiwan) SiranBio’s oligonucleotide candidate (known as “SA030”) targeting metabolic and vascular risk across lung, liver, and kidney disease.
A&O Shearman has advised global biopharma GSK on its licensing agreement with Frontier Biotechnologies Inc., a research-based, commercial-stage, publicly-traded biopharma company dedicated to the discovery, development, manufacture, and commercialization of innovative medicines, under which Frontier will exclusively license two of its small interfering RNA pipeline products to GSK on a worldwide basis.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
